
Vertex to Present Phase 3 Data on Suzetrigine as a Pain Signal Inhibitor at ASA Meeting
Vertex Pharmaceuticals (Nasdaq: VRTX) announced that it will present Phase 3 data on suzetrigine, an investigational oral NaV1.8 pain signal inhibitor for moderate-to-severe acute pain, at the American Society of…












